Company News: Pfizer

Share this article:
Pfizer said it will supply its Prevnar 13 pediatric vaccine to impoverished countries for 10 years under the terms of a UNICEF pilot project aimed at fighting pneumococcal disease, the leading cause of vaccine-preventable death for children under 5 globally. Under the terms of an Advance Market Committment agreement, Pfizer has agreed to charge no more than $3.50 per dose for 10 years to meet long-term demand and ensure affordability of the vaccine in developing countries even after the donor contributions are exhausted.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

FDA approves Glaxo's GLP-1

Type-2 diabetes injection Tanzeum, also known as albiglutide, scored the approval Tuesday.

Insurers get personal to nip costs

Healthcare insurers seek to curb diabetes costs with interventions that may include house calls.

Novartis dials down RNA research

The drugmaker says the therapeutic approach has a narrow treatment potential.